An optimized process extracts voacangine from Voacanga africana root bark using a direct acetone-based procedure, yielding approximately 0.8% of the dried root bark weight. The major alkaloids isolated are iboga-vobasinyl dimers, such as voacamine and voacamidine, which constitute about 3.7% of the bark. Because these dimers contain the voacangine moiety, a further optimized cleavage step produces additional voacangine at about 50% isolated molar yield. Applying both extraction and dimer cleavage nearly doubles the total voacangine obtained from the plant material compared to direct extraction alone.
Noribogaine, the primary metabolite of ibogaine, produces sexually dimorphic effects in mice, with some responses depending on the 5-HT2A receptor. A single 40 mg/kg dose reduced locomotion in male but not female wild-type mice. Gene expression of immediate early genes and glutamate receptors differed by sex and genotype. 5-HT2A receptor mRNA increased in the medial prefrontal cortex after noribogaine at 10 mg/kg in males and 40 mg/kg in females. Electrophysiology showed that 40 mg/kg reduced NMDA-mediated postsynaptic current density in layer V pyramidal neurons of the medial prefrontal cortex only in male wild-type mice, an effect absent in 5-HT2A receptor knockout males and all females. The genetic removal of the 5-HT2A receptor blunted noribogaine's effects on NMDA synaptic transmission.